NasdaqGM:NEOS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. More Details


Snowflake Analysis

Reasonable growth potential with imperfect balance sheet.


Similar Companies

Share Price & News

How has Neos Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NEOS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: NEOS's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-9.6%

NEOS

-1.1%

US Pharmaceuticals

-0.4%

US Market


1 Year Return

-44.6%

NEOS

9.2%

US Pharmaceuticals

36.2%

US Market

Return vs Industry: NEOS underperformed the US Pharmaceuticals industry which returned 9.1% over the past year.

Return vs Market: NEOS underperformed the US Market which returned 36.3% over the past year.


Shareholder returns

NEOSIndustryMarket
7 Day-9.6%-1.1%-0.4%
30 Day-11.2%-3.1%-2.3%
90 Day25.2%1.8%5.0%
1 Year-44.6%-44.6%12.9%9.2%39.1%36.2%
3 Year-91.4%-91.4%23.7%14.0%48.4%39.0%
5 Year-92.9%-92.9%43.8%26.8%116.6%92.4%

Long-Term Price Volatility Vs. Market

How volatile is Neos Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Neos Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Neos Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Neos Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Neos Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

60.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NEOS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: NEOS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NEOS's is expected to become profitable in the next 3 years.

Revenue vs Market: NEOS's revenue (17.3% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: NEOS's revenue (17.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NEOS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Neos Therapeutics performed over the past 5 years?

16.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NEOS is currently unprofitable.

Growing Profit Margin: NEOS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NEOS is unprofitable, but has reduced losses over the past 5 years at a rate of 16% per year.

Accelerating Growth: Unable to compare NEOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEOS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-4.3%).


Return on Equity

High ROE: NEOS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Neos Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: NEOS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NEOS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NEOS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: NEOS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NEOS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NEOS has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 9.5% each year.


Next Steps

Dividend

What is Neos Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NEOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NEOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NEOS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NEOS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NEOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Jerry McLaughlin (52 yo)

2.75yrs

Tenure

US$1,374,155

Compensation

Mr. Gerald W. McLaughlin, also known as Jerry, MBA has been the Chief Executive Officer and President of Neos Therapeutics, Inc. since joined it on June 27, 2018 and its Director since June 2018. Mr. McLau...


CEO Compensation Analysis

Compensation vs Market: Jerry's total compensation ($USD1.37M) is above average for companies of similar size in the US market ($USD516.25K).

Compensation vs Earnings: Jerry's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Gerald McLaughlin
CEO, President & Director2.75yrsUS$1.37m0.049%
$ 18.9k
Richard Eisenstadt
CFO, Treasurer & Corporate Secretary6.83yrsUS$647.25k0.059%
$ 22.6k
Margaret Cabano
Vice President of Operationsno datano datano data
John Limongelli
Senior VP2yrsUS$678.95k0%
$ 0
Joe Calarco
Chief Compliance Officer3.08yrsno datano data
Sarah Foster
Vice President of Human Resources1.58yrsno datano data
Russ McMahen
Senior Vice President of Research & Development3.17yrsno datano data

2.9yrs

Average Tenure

52yo

Average Age

Experienced Management: NEOS's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gerald McLaughlin
CEO, President & Director2.75yrsUS$1.37m0.049%
$ 18.9k
Bryant Fong
Independent Director11.75yrsUS$85.50k0.0030%
$ 1.2k
Beth Hecht
Independent Director5.5yrsUS$65.40k0%
$ 0
John Schmid
Independent Director5.75yrsUS$91.75k0%
$ 0
Alan Heller
Independent Chairman11.75yrsUS$98.63k0.85%
$ 326.0k
Gregory Robitaille
Independent Director11.75yrsUS$90.50k0.11%
$ 42.9k
Linda Szyper
Independent Director2.92yrsUS$81.75k0%
$ 0
James Robinson
Independent Director2.17yrsUS$91.86k0%
$ 0

5.6yrs

Average Tenure

55yo

Average Age

Experienced Board: NEOS's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Neos Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Neos Therapeutics, Inc.
  • Ticker: NEOS
  • Exchange: NasdaqGM
  • Founded: 2009
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$38.313m
  • Shares outstanding: 49.76m
  • Website: https://www.neostx.com

Number of Employees


Location

  • Neos Therapeutics, Inc.
  • 2940 North Highway 360
  • Suite 400
  • Grand Prairie
  • Texas
  • 75050
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NEOSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2015
NTEDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2015

Biography

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technolog...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/07 00:45
End of Day Share Price2021/03/05 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.